TriSalus Life Sciences, Inc. (TLSI)
NASDAQ: TLSI · Real-Time Price · USD
4.490
-0.010 (-0.22%)
Apr 28, 2026, 4:00 PM EDT - Market closed
TriSalus Life Sciences Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for TriSalus Life Sciences stock has a target of 7.00, which predicts an increase of 55.90% from the current stock price of 4.49.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 9, 2026.
Analyst Ratings
According to 1 stock analyst, the rating for TriSalus Life Sciences is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 1 | 1 |
| Buy | 3 | 1 | 1 | 1 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 3 | 3 | 3 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $7 | Strong Buy | Maintains | $7 | +55.90% | Mar 9, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $12 → $7 | Strong Buy | Maintains | $12 → $7 | +55.90% | Mar 6, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $11 → $12 | Strong Buy | Maintains | $11 → $12 | +167.26% | Dec 17, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $11 | Strong Buy | Maintains | $11 | +144.99% | Mar 28, 2025 |
| Roth MKM | Roth MKM | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +144.99% | Jan 24, 2025 |
Financial Forecast
Revenue This Year
61.16M
from 45.15M
Increased by 35.45%
Revenue Next Year
84.14M
from 61.16M
Increased by 37.58%
EPS This Year
-0.38
from -1.84
EPS Next Year
-0.07
from -0.38
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 63.9M | 95.9M | ||||||
| Avg | 61.2M | 84.1M | ||||||
| Low | 57.6M | 73.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 41.6% | 56.8% | ||||||
| Avg | 35.5% | 37.6% | ||||||
| Low | 27.5% | 20.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.28 | 0.22 | |
| Avg | -0.38 | -0.07 | |
| Low | -0.45 | -0.25 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.